Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Fritz G Buchanan"'
Autor:
William N Pappano, Jun Guo, Yupeng He, Debra Ferguson, Sujatha Jagadeeswaran, Donald J Osterling, Wenqing Gao, Julie K Spence, Marina Pliushchev, Ramzi F Sweis, Fritz G Buchanan, Michael R Michaelides, Alexander R Shoemaker, Chris Tse, Gary G Chiang
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0131716 (2015)
Histone methyltransferases are epigenetic regulators that modify key lysine and arginine residues on histones and are believed to play an important role in cancer development and maintenance. These epigenetic modifications are potentially reversible
Externí odkaz:
https://doaj.org/article/22fb11e246334a9a820a7722967d47ee
Autor:
Stephen K. Tahir, Emiliano Calvo, Benedito A. Carneiro, Junichiro Yuda, Aditya Shreenivas, Mojca Jongen-Lavrencic, Eelke Gort, Kenichi Ishizawa, Daniel Morillo, Carla Biesdorf, Morey Smith, Dong Cheng, Monica Motwani, David Sharon, Tamar Uziel, Dimple A. Modi, Fritz G. Buchanan, Susan Morgan-Lappe, Bruno C. Medeiros, Darren C. Phillips
Publikováno v:
Blood, 141(17), 2114-2126. American Society of Hematology
Activation of apoptosis in malignant cells is an established strategy for controlling cancer and is potentially curative. To assess the impact of concurrently inducing the extrinsic and intrinsic apoptosis-signaling pathways in acute myeloid leukemia
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal tissue expression represents a significant toxicity risk. The anti-EGFR antibody ABT-806 targets a unique tumor-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7af9a53ea623c6dab8499fd2219a76bc
https://doi.org/10.1158/1535-7163.c.6538540.v1
https://doi.org/10.1158/1535-7163.c.6538540.v1
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Amino Acid Sequence of AM-1 VH Region
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4690d3c6ba234726f181827c74d28b66
https://doi.org/10.1158/1535-7163.22505197
https://doi.org/10.1158/1535-7163.22505197
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Table S1: Mouse Strains Used for Xenograft Studies; Table S2: ABT-414 Growth Inhibition of Xenograft Tumors; Figure S1: Efficacy of ABT-414, ABT-806-vcMMAE, and unconjugated MMAE co-dosed with ABT-806 in U87MGde2-7 Tumor-Bearing Mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161f204be3c985a50dfa14ac1e0540f9
https://doi.org/10.1158/1535-7163.22506979
https://doi.org/10.1158/1535-7163.22506979
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead. Depatux-m has demonstrated promising clinical activity in glio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::313f2d242d9ae4aea09b4db055c77042
https://doi.org/10.1158/1535-7163.c.6537985.v1
https://doi.org/10.1158/1535-7163.c.6537985.v1
Autor:
Susan E. Morgan-Lappe, Bruce Trela, Nandini Rudra-Ganguly, Xin Lu, Enrico DiGiammarino, Li Zhou, Zhihong Liu, Nan Xu, Vivek C. Abraham, Deborah Widomski, Haichao Zhang, Morey L. Smith, Stephen K. Tahir, John Xue, Yu Xiao, Larry R. Solomon, Dong Cheng, Fritz G. Buchanan, Darren C. Phillips
TRAIL can activate cell surface death receptors, resulting in potent tumor cell death via induction of the extrinsic apoptosis pathway. Eftozanermin alfa (ABBV-621) is a second generation TRAIL receptor agonist engineered as an IgG1-Fc mutant backbon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f4891c38c60fc680a82c4ffe4a4054b
https://doi.org/10.1158/0008-5472.c.6513118.v1
https://doi.org/10.1158/0008-5472.c.6513118.v1
Autor:
Susan E. Morgan-Lappe, Bruce Trela, Nandini Rudra-Ganguly, Xin Lu, Enrico DiGiammarino, Li Zhou, Zhihong Liu, Nan Xu, Vivek C. Abraham, Deborah Widomski, Haichao Zhang, Morey L. Smith, Stephen K. Tahir, John Xue, Yu Xiao, Larry R. Solomon, Dong Cheng, Fritz G. Buchanan, Darren C. Phillips
Supplementary file containing all supplementary figures and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2db6562686474b129ae3c2ba189ca0b2
https://doi.org/10.1158/0008-5472.22428736.v1
https://doi.org/10.1158/0008-5472.22428736.v1
Autor:
Deborah Widomski, Vivek C. Abraham, Darren C. Phillips, Fritz G. Buchanan, Zhihong Liu, Stephen K. Tahir, Haichao Zhang, John Xue, Nandini Rudra-Ganguly, Xin Lu, Dong Cheng, Enrico L. Digiammarino, Morey L. Smith, Yu Xiao, Larry R. Solomon, Susan E. Morgan-Lappe, Bruce Trela, Nan Xu, Li Zhou
Publikováno v:
Cancer Research. 81:3402-3414
TRAIL can activate cell surface death receptors, resulting in potent tumor cell death via induction of the extrinsic apoptosis pathway. Eftozanermin alfa (ABBV-621) is a second generation TRAIL receptor agonist engineered as an IgG1-Fc mutant backbon
Autor:
Min Cheng, Dong Cheng, Wenqing Gao, Fritz G. Buchanan, Jun Guo, Sarah R. Mudd, Chris Tse, Julie L. Wilsbacher, Martin J. Voorbach
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:583-589
Cancer cells are highly dependent on NAD+/NADH produced via the nicotinamide salvage pathway. The rate-limiting enzyme in this pathway is the nicotinamide phosphoribosyltransferase (NAMPT), which we have targeted with novel NAMPT inhibitors. NAMPT in